US firm Johnson & Johnson is likely to apply for EU approval for its Covid-19 vaccine candidate in February, a top lawmaker said on Wednesday.
Clinical data of the vaccine, which Johnson & Johnson is developing through its subsidiary Janssen, have been assessed by the European Medicines Agency (EMA) since Dec. 1 under a rolling review to speed up possible approval.
Today, the Commission has published guidance to ensure that clinical trials can continue taking place in the EU during the COVID-19 pandemic. The aim is to mitigate the disruption of clinical research in Europe and therefore the negative effects of the pandemic, without compromising on quality and safety.
European Union health ministers met in Brussels on Thursday for an emergency summit to discuss a coordinated response to prevent the spread of the new coronavirus. Greece's Vassilis Kikilias recommended a digital platform that would allow member-states' crisis management authorities to exchange information related to the health scare in real time.